Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CIT | O14578 | 2/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.35 |
| ▸ | CTSA | P10619 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10189426 | 1.00 | CIT (0.38) | CITAAK1CTSAALDH1A1CASR | |
| SCHEMBL10242411 | 0.95 | CIT (0.40) | CITAAK1ALDH1A1CASRGPR142 | |
| SCHEMBL10241284 | 0.95 | CIT (0.40) | CITAAK1ALDH1A1CASRGPR142 | |
| SCHEMBL10189432 | 0.93 | CIT (0.38) | CITAAK1ALDH1A1GPR142LMNA | |
| SCHEMBL10189433 | 0.93 | CIT (0.38) | CITAAK1ALDH1A1GPR142LMNA | |
| SCHEMBL10189427 | 0.92 | S1PR1 (0.38) | CITAAK1CASRGPR142LMNA | |
| SCHEMBL10189429 | 0.92 | S1PR1 (0.38) | CITAAK1CASRGPR142LMNA | |
| SCHEMBL10189378 | 0.89 | LMNA (0.38) | CITAAK1ALDH1A1LMNA | |
| SCHEMBL10189431 | 0.88 | CIT (0.35) | CITAAK1ALDH1A1GPR142LMNA | |
| SCHEMBL10189430 | 0.88 | CIT (0.35) | CITAAK1ALDH1A1GPR142LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SUN LIJUN (US) | 2013-08-08 | — | — | US | disclosed |
| US-8399435-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040937-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | CIT 337/4885AAK1 3020/4885CTSA 1710/4885 |
| US-20130203824-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | CIT 337/4885AAK1 3020/4885CTSA 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.